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Dr Verrier. Thank you. I also think the effect of the reopera-
tion that occurs cannot be understated because certainly most of us
have abandoned the homograft except in endocarditis because
when you have to reoperate on a calcified root in a young person,
it is one of the most daunting operations we perform.
Dr Dagenais. I totally agree.
Dr D. Craig Miller (Stanford, Calif). Francois, nice presenta-
tion, but I cannot let you get away with censoring all these
“noncardiac deaths.” I know you did not have autopsies, or did
you? How do you know that those 18 deaths, a lot of which were
probably sudden and unexplained, were not of a cardiac cause?
That has been a bugaboo in any valve series, and the only way to
conservatively approach it is to consider them all, knowing that
you are probably overestimating the incidence of cardiac death, but
at least you are not letting something that smells bad creep into
your data. What would those curves look like with all deaths?
Dr Dagenais. We are the only center to which 3 million
persons are referred, and we have 2 nurses who are truly dedicated
to follow these patients. Most of these patients have autopsies
when they die. I think in such circumstances it is difficult to keep
the noncardiac deaths in the analysis considering the age differ-
ence between the groups. This is, however, a study limitation.
When you include the noncardiac deaths, there was a trend toward
lower survival in the Freestyle and the stented xenograft groups.
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